Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. The company's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd. has received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for SHR-6934 injections and will conduct clinical trials in the near future. SHR-6934 injection is a biological product intended for the treatment of heart failure.

Zhitongcaijing · 10/15 07:41
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. The company's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd. has received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for SHR-6934 injections and will conduct clinical trials in the near future. SHR-6934 injection is a biological product intended for the treatment of heart failure.